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Expert Opinion On Drug Safety 
RA Chudleigh 
Consultant Physician, Singleton Hospital, Swansea SA2 8QA 
SC Bain 
Professor of Medicine (Diabetes), Diabetes Research Unit Cymru, Swansea SA2 8PP 
Abstract 
Introduction: Liraglutide is a GLP-1 RA that is an option for treatment of T2DM. Typical of 
all new glucose-lowering agents, its CV safety profile is of great interest. 
Areas covered: This article outlines the efficacy of the GLP-1 RA liraglutide from RCTs, 
moving through the pivotal phase 3 LEAD trials, and subsequent meta-analyses to assess CV 
safety. This review describes evolution of regulatory requirements to obtain safety 
information through dedicated CVOTs.  
Expert opinion: Since the FDA mandated that CV outcomes for new diabetes therapies 
should be assessed via a dedicated CVOT, opinion of their utility in T2DM evolved from 
cynicism through to enthusiasm. In LEADER, liraglutide became the second modern 
glucose-lowering agent to demonstrate significant CV benefit. CVOTs are now providing 
important answers, highlighting the CV benefits of modern glucose-lowering agents, but also 
raising several questions, notably whether the effects seen with liraglutide and empagliflozin 
are class-effects or are unique to these molecules. Furthermore it is unknown if these results 
in patients with high CV risk are applicable to all patients with T2DM, and should be 
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incorporated into new treatment guidelines. In our view it’s prudent to suggest that CVOT 
findings cannot currently be extrapolated to the whole T2DM population. 
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Article highlights 
 Liraglutide efficacy versus a wide range of comparator diabetes therapies was shown 
by the Phase 3 LEAD studies. A subsequent meta-analysis then showed there to be no 
increase in major adverse cardiovascular events caused by liraglutide. 
 In 2008 the FDA and subsequently the EMA mandated that new therapies for diabetes 
should be assessed via CVOTs, leading to mixed results and interpretations.   
 In the LEADER trial, liraglutide significantly reduced the risk of the primary 
composite CV outcome, and lowered the risk of death from CV causes and death from 
any cause, compared with placebo, both in addition to standard of care. 
 LEADER, as with other completed CVOTs, has raised fundamental questions 
concerning interpretation of the results, such as are effects seen class-effects or unique 
to individual molecules? Furthermore do CVOT results apply to all patients with 
T2DM and should therefore lead to changes in the treatment guidelines? 
 Current CVOT findings cannot be extrapolated to the whole T2DM population, 
although some national guidelines have already made recommendations based on 
evidence from CVOTs.  
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1. Introduction 
The global prevalence of diabetes is approximately 8.8%, equating to around 415 million 
people with this chronic condition [1]. Type 2 diabetes mellitus (T2DM) accounts for at least 
95% of cases and, driven by rising rates of obesity, the prevalence of T2DM is set to increase. 
If inadequately controlled, T2DM increases the risk of large vessel disease (myocardial 
infarction [MI], stroke and amputation) and small vessel complications (visual loss, renal 
disease and neuropathy).  
In addition to lifestyle modification (diet and exercise), there are now several different classes 
of glucose-lowering pharmacotherapy - eight in Europe and ten in the United States. Despite 
this, achievement of adequate glycemic control remains a challenge owing to the progressive 
decline of pancreatic beta-cell function. This necessitates treatment intensification, with step-
wise addition of therapy classes, ultimately leading to the use of insulin [2]. Many diabetes 
treatment guidelines recommend a patient-centered approach with the aim of achieving 
individualized hemoglobin A1c (HbA1c) targets while avoiding adverse effects, especially 
hypoglycemia and weight gain [3, 4]. 
 
2. Glucagon-like peptide-1  
Glucagon-like peptide-1 (GLP-1) is a hormone that increases insulin secretion and decreases 
glucagon production from pancreatic islets in a glucose-dependent manner; ‘glucose 
dependent’ means that these effects are only seen when glucose levels are elevated. GLP-1 
receptor agonist drugs (GLP-1 RAs) produce the equivalent of a pharmacologic level of 
GLP-1. These drugs reduce hyperglycemia and weight by increasing insulin secretion and 
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decreasing glucagon secretion while they also delay gastric emptying and increase satiety. 
Currently, all of the GLP-1 RA agents are administered as a subcutaneous (SC) injection [5].  
Although the rates of adverse effects differ between GLP-1 RAs, the most common side-
effects within the class are gastrointestinal (nausea, vomiting, and diarrhea) along with 
injection-site reactions. There are currently six GLP-1 RAs available for use in Europe: in 
order of license approval, these are exenatide (as Byetta™) given twice daily, liraglutide 
administered once daily, exenatide (as Bydureon™) once weekly, lixisenatide once daily and 
most recently albiglutide and dulaglutide, both once weekly.  
The GLP-1 RAs are attractive options for the treatment of T2DM because they effectively 
lower HbA1c and weight while having a low risk of hypoglycemia. 
 
3. Liraglutide 
Liraglutide is a GLP-1 analogue that has 97 % amino acid sequence homology to endogenous 
human GLP-1 (7–37) [6, 7, 8]. It has been designed by a single amino acid substitution of 
lysine with arginine at position 34 and the attachment of a C16 fatty acid chain to lysine at 
position 26. These changes allow liraglutide to self-associate, delaying absorption from the 
SC injection site, while providing protection from degradation by the ubiquitous dipeptidyl 
peptase-4 (DPP-4) enzyme and other endopeptidases. This allows liraglutide to have a much 
longer half-life than endogenous GLP-1 (around 13 hours versus 1–2 minutes) [7, 8]. 
Liraglutide activates the GLP-1 receptor, which in the pancreatic beta-cells, is a membrane 
bound cell-surface receptor coupled to adenyl cyclase by a stimulatory G-protein [8]. 
Activation of the receptor creates an increase in intracellular cyclic monophosphate and, as a 
consequence, a dose-dependent insulin release in patients with hyperglycemia. In concert 
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with this effect, liraglutide acts in a glucose-dependent manner to decrease inappropriately 
high glucagon secretion (typically present in T2DM), thereby reducing hepatic glucose 
production. [7, 8, 9]. In addition to these direct gluco-regulatory effects, liraglutide increases 
satiety, probably by a central nervous mechanism, and delays gastric emptying, albeit it to a 
lesser extent than is seen with shorter-acting GLP-1 RAs (such as lixisenatide). The 
consequent reduction in hunger and lower energy intake lead to a fall in bodyweight and 
contribute to the beneficial effects of liraglutide in patients with T2DM [10, 11]. 
The Liraglutide Effect and Action in Diabetes (LEAD™) trial program was a pre-registration 
series of studies of liraglutide in patients with T2DM. It consisted of six randomized, 
controlled, parallel-group trials investigating the drug across the spectrum of T2DM: as 
monotherapy [12], in combination with a sulfonylurea (SU) [13], in combination with 
metformin [14], as a triple combination with a thiazolidinedione and metformin [15], as a 
triple combination with an SU and metformin versus insulin glargine [16] and as a 
combination with metformin and/or SU in a head-to-head comparison with exenatide [17]. 
Another head-to-head trial, performed after the LEAD program, investigated liraglutide 
versus sitagliptin, both in combination with metformin [18]. These studies were designed to 
cover the continuum of T2DM with a primary efficacy endpoint of change in HbA1c: other 
glycemic endpoints included attainment of HbA1c targets; changes in fasting plasma glucose; 
and plasma glucose profiles. Body weight and surrogate cardiovascular endpoints such as 
blood pressure and lipid profiles were also measured. Safety endpoints included 
hypoglycemia, pancreatitis, liraglutide antibodies and hematological and biochemical tests 
such calcitonin (due to the elevated risk of C-cell malignancy reported in rodent animal 
models [19]).  
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Overall the LEAD program showed that liraglutide lowered HbA1c to the same degree or a 
greater extent than other antidiabetic drugs. It also induced weight loss and improved β-cell 
function, blood pressure and some cardiovascular risk markers. Liraglutide was well tolerated 
with the most frequently reported adverse effect being transient nausea. A thorough corrected 
QT study also showed that steady-state concentrations of liraglutide did not produce 
prolongation of the corrected QT interval on ECG, a known risk factor for cardiovascular 
(CV) events [20]. In further support of the LEAD program, a number of retrospective and 
observational studies have also shown that liraglutide reduces major cardiovascular disease 
(CVD) risk factors in real-world settings [21, 22]. 
 
4. Cardiovascular outcome trials 
CVD is the leading cause of mortality and adverse outcomes in patients with T2DM. More 
than 60% of patients die from CVD while an even greater proportion suffer serious CV-
associated co-morbidities [23]. T2DM imparts a two-to-fourfold increase in the risk of 
coronary heart disease and life expectancy is reduced by 6-7 years for those aged 40 years 
and over [23, 24]. Despite this consistent correlation with negative outcomes, it has been 
difficult to establish that tight glycemic control reduces CV events [25, 26, 27, 28]. Indeed, 
the CV safety of glucose-lowering drugs was not routinely investigated until the 2008 United 
States (US) Food and Drug Administration (FDA) [29] declaration that all new therapies for 
diabetes should undergo a rigorous assessment of safety through large-scale cardiovascular 
outcome trials (CVOTs). This advice was subsequently reinforced by the European 
Medicines Agency (EMA) [30]. 
The FDA recommendations followed on from a meta-analysis which suggested that the 
thiazolidinedione rosiglitazone increased the risk of MI and heart failure (HF) in patients with 
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T2DM [31, 32]. Despite a subsequent trial [33, 34] showing only an excess risk for HF 
without any definitive results on MI, rosiglitazone’s license was withdrawn in Europe and 
severely restricted in the US. The requirements for CVOTs that were produced in the 2008 
FDA guideline included the following [29, 35]: 
 A prospective independent adjudication of CV events in Phase 2 and 3 studies, so as 
to allow for a meta-analysis of CV events in all placebo-controlled, add-on (drug vs. 
placebo, plus standard therapy) and active-controlled trials.  
 If the meta-analysis of Phase 2 and 3 trials demonstrates an upper bound of the 95% 
confidence interval for the risk of major adverse cardiac events (MACE) of below 1.8 
but above 1.3, compared with placebo, then a single, large, CVOT should be 
conducted on high-risk populations, including those with advanced disease, elderly 
and those with renal impairment, and lasting for at least two years. 
 CV events were to include CV mortality, MI and stroke, and possibly hospitalization 
for acute coronary syndromes, urgent revascularization and other end-points 
 In order to exclude unacceptable CV risk, a two-sided 95 % confidence interval (CI) 
upper boundary of 1.8 risk ratio (pre-approval) and/or 1.3 risk ratio (post-approval) 
for MACE versus control group was required. 
Because the results of previous trials evaluating glucose-lowering therapies could not exclude 
a CV benefit from tight glycemic control, the CVOTs which have followed on from the FDA 
regulation have focused on maintaining ‘glycemic equipoise’. This means that investigators 
should attempt to produce equivalent lowering of HbA1c in both the active and placebo 
cohorts, so that the CV effect of the drug itself can be examined. This is achieved by allowing 
add-on of additional glucose-lowering therapies in the placebo arm [36]. There was also a 
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presumption that other CV risk factors, such as blood pressure and low-density lipoprotein 
cholesterol would be appropriately managed - so-called ‘standard of care’. 
Following on from these statutory requirements, the CV safety of liraglutide has been 
assessed by both meta-analyses of CV events in Phase 2 and 3 studies and a post-approval 
CVOT, known as LEADER (Liraglutide effect and action in diabetes: Evaluation of 
Cardiovascular Outcome Results) 
 
5. Liraglutide Phase 2/3 cardiovascular meta-analysis 
The objective of this analysis was to identify and report rates of MACE among patients 
randomized to liraglutide versus comparator using data from the liraglutide T2DM clinical 
development program [37]. All patient-level CV safety data from the completed Phase 2 and 
3 randomized trials of liraglutide, plus open-label extensions were pooled. Since an 
assessment of MACE had not been pre-specified, a systematic approach was adopted to 
identify CV events (Table 1).  
Table 1: Systematic approach for identifying CV events 
 
 Systematic approach for identifying CV events 
1 Possible events were identified through queries of the study database using a 
classification system for adverse event and safety assessment: 
 Three standardized MedDRA searches – broad, narrow, and custom – were 
performed using the categories of ‘myocardial infarction’, ‘central nervous 
system hemorrhage and cerebrovascular accidents’, and ‘cardiovascular death.’  
 For MI and stroke, the broad query resulted in 28 and 125 terms; narrow 
included 10 and 95; and custom included six and 30 respectively. It is of note 
that all of these data had been requested by the FDA prior to their final 
regulatory review of liraglutide in 2009 [37] 
2 All MACE identified in the MedDRA query were classified as serious or non-serious 
adverse events, according to the view of site investigators 
3 All candidate serious MACE were adjudicated post hoc by two investigators who were 
blinded to treatment. MI and stroke were pre-specified as ‘definite’, ‘probable’, 
‘unlikely’, ‘definitely not’, or ‘unknown’ 
MedDRA - Medical Dictionary for Regulatory Activities - terms)[38] 
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Table 2: characteristics of patients included in the meta-analysis 
Number of studies included 15 
Number of subjects  6,638 (4,257 exposed to liraglutide) 
Age of subjects (years) 55±11  
Baseline HbA1c (%) 8.4±1.0 
Males: Females (%) 53:47 
Duration of diabetes (years) 7±6  
Total drug exposure (years) 2,882 (liraglutide) / 1,486 (comparators) 
Patients with CVD (%) 25% 
Patients on: monotherapy (%) 
combination therapy (%) 
32.6% 
60.6%  
 
 
Characteristics of patients included in this meta-analysis are shown in Table 2. Using the 
MedDRA broad, narrow, and custom criteria respectively, 114, 59, and 38 patients with 
MACE were initially identified. The overall incidence rate of adjudicated MACE associated 
with the broad MedDRA query was 0.9%. For each MedDRA search, the incidence ratio for 
adjudicated MACE associated with liraglutide was <1.0 and the upper 95% CI was <1.8; 
these both fell within the cardiovascular safety limits predefined by the US FDA for diabetes 
therapies under current investigation [29]. 
There were clearly issues that limited any definitive conclusions from this study and these 
were acknowledged by the authors. Low statistical power, enrolment of low-risk CV patients, 
and lack of pre-specified CV endpoints with independent adjudication in the drug 
development program were listed. In addition, there was heterogeneity in the use of 
comparator therapies, ranging from placebo to active comparators consisting of various oral 
and injectable anti-diabetic drugs. Although MACE were independently adjudicated by 
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blinded clinicians, it was also acknowledged that CV events may not have been identified by 
MedDRA search strategies. 
In 2015, a further meta-analysis was performed, this time as part of the regulatory submission 
for liraglutide as a weight management (WM) agent, where it is recommended at a dose of 
3.0 mg OD (versus the highest dose of 1.8mg OD for the treatment of T2DM) [40, 41]. The 
primary analysis included all available individuals from five randomized, controlled Phase 2 
and 3 liraglutide WM trials (including data from an additional 120-day safety follow-up 
period). It examined the time from first date of drug administration to first occurrence of 
MACE for total liraglutide arms versus the total comparator arms. MACE were defined as 
CV death, non-fatal MI and non-fatal stroke (so-called 3-point MACE). MACE were 
prospectively adjudicated for three of the five WM trials with post-hoc adjudication 
conducted for the other two. Individuals who did not experience an event during the 
treatment period or within 30 days after last dose were censored at last treatment date plus 30 
days. A further secondary analysis examined the time to first MACE for total liraglutide 
versus total comparator in the T2DM pool, which by then included additional studies. Data 
for this supportive analysis were provided from twenty-one randomized, controlled Phase 2 
and 3 trials from the clinical development programs in T2DM where liraglutide was used in 
at least one treatment arm at doses of up to 1.8 mg OD. 
Data from a total of 5,908 individuals across the liraglutide WM trials (liraglutide n=3,872; 
comparator n=2,036) and 8,259 individuals across T2DM trials (liraglutide n=5511; 
comparator n=2,748) were included in the analyses. In the primary analysis across WM trials 
the overall number of adjudicated MACE was low for both liraglutide and comparator, but 
numerically lower with liraglutide (total liraglutide: 10 events, frequency 0.2%, 0.2 events/ 
100 patient-years of exposure [PYE]; liraglutide 3.0 mg: 7 events, 0.2%, 0.2 events/100 PYE) 
than with comparator (total comparator: 10 events, 0.5%, 0.4 events/100 PYE; placebo: 10 
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events, 0.5%, 0.4 events/100 PYE). The hazard ratio (HR) for total liraglutide vs. total 
comparator (primary analysis) was 0.40 (95% confidence interval [CI]: 0.16; 1.01). In the 
secondary analysis of T2DM trials, higher event rates were observed compared with the 
analysis of WM trials, but as in the earlier meta-analysis, these were numerically lower in the 
liraglutide-treated cohort; total liraglutide: 26 events, 0.5%, 0.6 events/100 PYE vs. total 
comparator: 23 events, 0.8%, 1.3 events/100 PYE. HR was 0.64 (95% CI: 0.35; 1.15). 
The conclusions from this second meta-analysis was that there was no indication of an 
increased risk of MACE with liraglutide at doses of up to 3.0 mg once-daily for WM in 
individuals with overweight/obesity with or without T2DM. Furthermore, there was no 
indication of an increased risk of MACE in individuals with T2DM with liraglutide up to 
doses of 1.8 mg OD.  
 
6. Liraglutide cardiovascular outcome trial 
The large, post-approval CVOT for liraglutide, known as LEADER, was simultaneously 
presented and published in June 2016 [42]. A total of 9,340 patients with T2DM were 
randomized, with 4,668 patients assigned to receive liraglutide and 4,672 in the placebo arm. 
A total of 96.8% of the subjects completed a final visit, died, or had a primary outcome and 
the vital status of trial participants was known in 99.7% of cases, indicating an extremely 
well-conducted study. The median time of exposure to liraglutide was 3.5 years and the mean 
percentage of time that patients received the trial regimen was 84% for liraglutide and 83% 
for placebo. The median daily dose of liraglutide was 1.78 mg and this included periods 
during which subjects did not receive study medication. The demographic and clinical 
characteristics of the patients were similar in the two groups with the majority (81.3%) 
having established cardiovascular disease, and the remainder being above 60 years of age 
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with at least one additional risk factor for CVD. At baseline, the mean duration of diabetes 
was 12.8 years, and the mean HbA1c was 8.7%. 
The primary outcome was the 3-point MACE, composed of CV death, non-fatal MI and non-
fatal stroke and this occurred in fewer patients in the liraglutide group (608 of 4,668 patients 
[13.0%]) than in the placebo group (694 of 4672 [14.9%]) (HR 0.87; 95% CI 0.78; 0.97; 
p < 0.001 for non-inferiority; p = 0.01 for superiority). Death from CV causes occurred less 
frequently in liraglutide patients (219 patients [4.7%]) than in the placebo group (278 [6.0%]) 
(HR 0.78; 95% CI 0.66; 0.93; p = 0.007). Death from any cause was also reduced in the 
liraglutide group (381 patients [8.2%]) compared with placebo (447 [9.6%]) (HR 0.85; 95% 
CI 0.74; 0.97; p = 0.02). The frequencies of non-fatal MI and non-fatal stroke were lower in 
the liraglutide group than in the placebo group, but these differences were not significant. 
Several sensitivity analyses were performed and these showed a similar magnitude of 
difference between the trial arms. 
In subgroup analyses, significant interactions were observed for an eGFR of 60 ml or more 
per minute per 1.73 m
2
 versus an eGFR of less than 60 ml per minute per 1.73 m
2
, with a 
benefit favoring the lower eGFR, and for the presence versus absence of established CVD at 
baseline, with benefit for those with CV disease at baseline. The pre-specified analysis of 
HbA1c at 36 months showed a mean difference of −0.40% (95% CI −0.45; −0.34) between 
the liraglutide group and the placebo group. The placebo group had significantly more 
additional hypoglycemic medication added in during the course of the study; notably there 
were more frequent treatment intensifications with both insulin and sulfonylureas (SUs). 
Concerning CV risk factors, there were significant differences between the liraglutide group 
and the placebo group in the change from baseline to 36 months in the following variables: 
weight loss was 2.3 kg (95% CI, 2.5; 2.0) more in the liraglutide group, systolic blood 
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pressure was 1.2 mm Hg (95% CI, 1.9; 0.5) lower in the liraglutide group, and heart rate was 
3.0 beats per minute (95% CI, 2.5; 3.4) higher in the liraglutide group. 
To summarize, in the LEADER trial, subjects in the liraglutide group had a lower risk of the 
primary composite outcome — first occurrence of CV death, nonfatal MI, or nonfatal stroke 
in the time-to-event analysis — and lower risks of death from CV causes and death from any 
cause than did those in the placebo group. The number that would need to be treated to 
prevent one primary outcome event in 3 years was 66. There had previously been concern 
about the risk of hospitalization for heart failure with the DPP-4 inhibitors, another incretin 
class of anti-diabetic medication [43]. In LEADER, there were fewer hospitalizations for 
heart failure among patients in the liraglutide group than among those on placebo, although 
this did not reach statistical significance. 
 
The CV benefits were observed on a background of generally acceptable levels of CV risk-
factor management (blood pressure, lipids and antiplatelet therapy) at baseline and during the 
trial. There were fewer add-on therapies for diabetes medications, lipid-lowering 
medications, platelet-lowering therapies and blood pressure-lowering therapies, and diuretics 
in patients in the liraglutide group than in those in the placebo group. Subgroup analyses 
suggested a greater benefit of liraglutide in patients with an eGFR of less than 60 ml per 
minute per 1.73 m
2
 and in patients with a history of CV disease.  
 
The pattern of CV benefit seen in LEADER was different to that seen with the sodium–
glucose co-transporter 2 inhibitor empagliflozin in the EMPA-REG OUTCOME study [44]. 
The time to benefit emerged earlier and the heterogeneity of the direction and magnitude of 
the effects on components of the (same) 3-point MACE in that trial contrasts with the 
consistency of the effect in LEADER. Although these differences may reflect patient 
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populations or chance, the authors suggested that the benefits in EMPA-REG OUTCOME 
may be explained by hemodynamic changes, whereas with liraglutide, the observed benefits 
may indicate modification of progression of atherosclerotic vascular disease [42][44]. 
 
The authors of the primary LEADER results publication noted that in the Evaluation of 
Lixisenatide in Acute Coronary Syndrome (ELIXA) trial, the GLP-1–receptor agonist 
lixisenatide did not show any CV benefit in patients with T2DM and a recent acute coronary 
syndrome [45]. The reasons behind the different results obtained with these two GLP-1RAs 
(lixisenatide and liraglutide) are unclear, but may be explained by differences in trial design 
(such as the short duration), or inherent properties resulting from their different molecular 
structures (exendin based versus human GLP-1 based) and durability of action. There are also 
several trials investigating CV outcomes in high-risk cohorts with T2DM where a similar 
difference in HbA1c to the one seen in LEADER had no impact on CV events or death. 
These include studies of basal analogue insulin [46] thiazolidinediones [31, 47] and three 
DPP-4 inhibitors [48, 49, 50] (Table 3). The LEADER trial had greater statistical power than 
most previous studies and included patients with a much higher baseline HbA1c. 
 
One possible reason for the positive outcome compared with other studies relates to 
hypoglycemia. Many patients in each group were treated with SUs or insulin at baseline, but 
fewer patients in the liraglutide group had insulin added during the trial. There was a 31% 
lower rate of severe hypoglycemia and a 20% lower rate of confirmed hypoglycemia (plasma 
glucose level <3.1 mmol/l) in the liraglutide group compared with the placebo group. Such a 
reduction in hypoglycemia for the active agent has not been observed in other CVOTs. 
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Of course the trial has limitations, as were acknowledged by the authors. For example, 
patients were followed for only 3.5 to 5.0 years and so the safety and efficacy data are 
restricted to that time period. Also, the trial recruited a population of patients who were at 
high risk for CV events and who had a high baseline HbA1c (of 8.7%), and so the outcomes 
may not be seen in T2DM patients at lower risk.  Additionally, patients were treated with 
liraglutide 1.8 mg, and although it may be possible to extrapolate the CV safety finding to 
patients receiving the lower dose of 1.2 mg, given the precise mechanisms for the CV 
benefits are presently unknown, this may merit additional investigation.
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Table 3: comparison of intervention, inclusion criteria and primary CV result from published CVOTs 
Trial Intervention
*
 N Inclusion criteria
† Primary CV result 
ELIXA [45] Lixisenatide 6,068 ACS within 180 days 
HR: 1.02a 
(p < 0.001 non-inferiority) 
(p = 0.81 for superiority) 
ORIGIN [46] Insulin glargine 12,537 CV risk factors 
HR: 1.02b  
(p = 0.63) 
HR: 1.04c  
(p = 0.27) 
PROactive [47] Pioglitazone 5,238 Established CVD 
HR: 0.90d  
(p = 0.095) 
RECORD [33] Rosiglitazone 4,447 CV risk factors HR: 0.99e  
SAVOR-TIMI-
53 [48] 
Saxagliptin 16,492 
Established CVD and/or multiple risk 
factors 
HR: 1.00f  
(p < 0.001 for non-inferiority) 
(p = 0.99 for superiority) 
EXAMINE [49] Alogliptin 5,380 ACS within 15-90 days 
HR: 0.96f 
(p < 0.001 for non-inferiority) 
TECOS [50] Sitagliptin 14,671 Age >50 + established CVD 
HR: 0.98a 
(p < 0.001 for non-inferiority) 
EMPA-REG [44] Empagliflozin 7,028 History of CVD 
HR: 0.86f 
(p < 0.001 non-inferiority) 
(p = 0.04 for superiority) 
LEADER [42] Liraglutide 9,340 
Age >50 + CVD or chronic renal 
failure, or age >60 + CV risk factors 
HR: 0.87f 
(p < 0.001 for non-inferiority) 
(p = 0.01 for superiority) 
 
ACS, acute coronary syndrome; CV, cardiovascular; CVD, cardiovascular disease; *Versus placebo; †All CVOTs included patients who were required to have type 2 diabetes, except the ORIGIN trial 
where patients could instead have pre-diabetes (impaired fasting glucose or impaired glucose tolerance); aCV death, Non-fatal MI, Non-fatal stroke or Hospitalization for unstable angina; bDeath 
from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke; ca composite of any of these events, a revascularization procedure (cardiac, carotid, or peripheral), or hospitalization 
for heart failure; dall-cause mortality, non-fatal myocardial infarction (including silent myocardial infarction), stroke, acute coronary syndrome, endovascular or surgical intervention on the coronary 
or leg arteries, or amputation above the ankle; ecardiovascular hospitalization or cardiovascular death; fCV death, Non-fatal MI or Non-fatal stroke
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7. Conclusions 
Liraglutide is now the second agent, and first in the GLP-1 RA class, to demonstrate a 
significant reduction in CV events in the setting of a modern CVOT. This reduction in the 
primary outcome of a 3-point MACE was largely driven by a significant fall in CV deaths, 
although the other two components (non-fatal MI and non-fatal stroke) showed a signal for 
benefit. The study outcome is also consistent with meta-analyses of Phase 2 and 3 clinical 
trial data, which included WM studies where the dose of liraglutide used is higher than that 
recommended for the management of T2DM. The time course for the reduction in CV 
endpoints is consistent with an effect on the atherogenic process although other effects 
including lower rates of hypoglycemia and differential additional of other hypoglycemic 
agents cannot be excluded. 
 
8. Expert opinion 
In 2008 the FDA mandated that all new glucose-lowering therapies should be shown not to 
increase the risk of cardiovascular (CV) events in patients with T2DM. The first four CVOTs 
conducted as a result of this direction (SAVOR TIMI 53, EXAMINE, TECOS and ELIXA) 
were positive, in that they showed no evidence of increased CV risk, which was the aim of 
the exercise. They did not reach the glycemic equipoise which was part of the trial protocol, 
but differences in HbA1c between the treatment arms were modest in each study (between 
0.2 and 0.4%). However, they also showed no evidence of CV benefit and so were widely 
regarded as neutral or negative, especially by clinicians who were unfamiliar with the study 
designs. Indeed, some questioned the utility of the drugs being tested since they appeared to 
have little impact on glycemic control (versus ‘placebo’) and did not reduce the large vessel 
complications of T2DM. 
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It is of note that for the three gliptins (saxagliptin, alogliptin and sitagliptin) which now have 
published CVOT data, meta-analyses (Phase 2 and 3 data) each suggested a favorable effect 
on CV outcomes (albeit without statistical significance).These CV benefits were not seen 
with the definitive CVOTs. This led some experts to further query the design of CVOTs, 
suggesting that only safety could be demonstrated. This was particularly the case for 
lixisenatide, a short-acting GLP-1 receptor agonist where patients in the ELIXA trial had all 
experienced a recent acute coronary syndrome and were only followed for a median of 25 
months. If lixisenatide has a beneficial CV effect, the likelihood of showing it in this setting 
was always going to be remote. 
 
There were other downsides. The SAVOR-TIMI 53 trial showed that more patients in the 
saxagliptin group were hospitalized for heart failure and a similar trend was seen for 
alogliptin in the EXAMINE CVOT. This led to doubts about the major adverse CV events 
(MACE) end-points being used in the studies – could the exclusion of heart failure be 
justified – and subsequently an FDA safety warning for both drugs regarding heart failure 
risk. 
 
So, 7 years after the FDA’s CV safety mandate, there was a great deal of cynicism regarding 
CVOTs in T2DM. It appeared that putative benefits of new drugs could not be demonstrated 
with the existing trial formats, all of which were extremely expensive and time-consuming. It 
was also uncertain if every new drug in a class would need assessment if several others had 
already been shown to be safe.  
 
It was on this background that the EMPA-REG OUTCOME study reported in 2015, 
completely turning the field on its head. In this study, a total of 7,020 patients were randomly 
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assigned to receive the sodium-glucose transporter 2 (SGLT-2) inhibitor empagliflozin or 
placebo for approximately 3 years. Empagliflozin significantly reduced the risk of the 
primary outcome (hazard ratio 0.86, 95% CI 0.74; 0.99), demonstrating not just non-
inferiority (p < 0.001), but also superiority (p = 0.04) compared with placebo. 
 
The result was largely driven by the significantly lower rate of death from cardiovascular 
causes in the empagliflozin group (38% relative risk reduction [RRR]) but beyond the 
primary endpoint and components, hospitalization for heart failure (35% RRR), and death 
from any cause (32% RRR) were also significantly reduced. It was of great interest that all of 
these beneficial effects were seen after only a few months of trial observation. 
 
Liraglutide became the second glucose-lowering agent to demonstrate significant CV benefit 
following the publication of the LEADER study in 2016.The positive results from EMPA-
REG OUTCOME and LEADER, highlight the CV benefits of modern glucose-lowering 
agents, but they also raise several interesting questions. Are the effects seen with liraglutide 
and empagliflozin likely to be class-effects or be unique to these molecules? The answer to 
this question remains to be seen but will be definitively answered by on-going trials (for 
example, the CANVAS and DECLARE studies for the other two currently licensed SGLT-2 
inhibitors, canagliflozin and dapagliflozin). In the ELIXA trial lixisenatide was not seen to 
confer any CV benefit compared with placebo, but recent results with the GLP-1RA 
semaglutide have made a class-effect appear more likely [50]. Semaglutide is a GLP-1 
receptor agonist with marked similarities to liraglutide but which has a longer half-life 
allowing for once-weekly administration. In the SUSTAIN 6 trial of 3,297 patients with 
T2DM and very similar CV co-morbidities to those enrolled in the LEADER study, the 3-
point MACE occurred in 6.6% of patients in the semaglutide group and in 8.9% of patients in 
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the placebo group (HR 0.74; 95% CI 0.58; 0.95; p < 0.001 for non-inferiority). A post-hoc 
analysis confirmed superiority with a p-value of 0.02. Interestingly, the primary end-point 
was driven by a significant reduction in non-fatal stroke and a non-significant reduction in 
non-fatal MI, with similar rates of death from CV causes in the two groups. This differs from 
LEADER and may simply be the play-of-chance or be related to the duration of observation. 
It should be noted that the SUSTAIN 6 study was much smaller and shorter than LEADER 
since it was a pre-license study, with consequently less robust criteria for non-inferiority (a 
CI margin of 1.8 versus that for LEADER – 1.3). Of interest, in SUSTAIN 6, diabetic 
retinopathy complications occurred in 50 patients (3.0%) in the semaglutide group and 29 
(1.8%) in the placebo group (HR 1.76; 95% CI, 1.11; 2.78; p = 0.02). Although retinopathy 
event numbers were low, direct causation of this effect by semaglutide cannot be ruled out; 
however, the generalizability across the GLP-1 class is unclear. Though no such treatment 
effect was observed with liraglutide in LEADER, there was also no benefit observed in 
regards to retinopathy [42]. 
What seems certain is that the mechanisms underlying the positive outcomes seen in EMPA-
REG OUTCOME and LEADER are different. The CV benefit seen with empagliflozin 
emerged very quickly, possibly implying a hemodynamic effect and being consistent with the 
dramatic fall in hospitalization due to heart failure. The effect of liraglutide was much more 
gradual which may point to a slowing of the atherogenic process [52]. There was also a signal 
for increased stroke seen with empagliflozin whereas all components of the primary end-
point in LEADER moved in the same beneficial direction, again emphasizing the potential 
differences between the drug effects. Whether the co-administration of a GLP-1 receptor 
agonist and a SGLT-2 inhibitor would produce complimentary CV benefits is unknown 
although a positive impact on HbA1c and weight has recently been demonstrated [53]. 
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It is also unclear as to what contribution the use of alternate glucose-lowering therapies in the 
placebo arm of LEADER may have made to the primary end-point reduction. The baseline 
HbA1c in LEADER was 8.7% at which point over 40% of patients were taking insulin and 
50% were prescribed sulfonylureas (SUs). The standard-of-care target during study was an 
HbA1c <7.0% and since other incretin drugs were not permitted (and SGLT-2 inhibitors had 
not been licensed), significantly more insulin and SU were prescribed for the placebo group. 
There remains the possibility that these agents increase CV risk and so some of the beneficial 
effect of liraglutide could be due to lower use of insulin and SUs. Their use could also 
account for the higher rates of hypoglycemia seen in the placebo group and this could, in 
turn, lead to an increased CV event rate. To an extent, this is an academic argument since if 
one accepts that an HbA1c of 8.7% is unacceptable for patients with T2DM at high CV risk, 
then reducing it with liraglutide rather than conventional drug classes appears to be a rational 
choice. 
 
A final question is whether these results apply to all patients with T2DM and hence should 
lead to changes in the treatment guidelines. The inclusion criteria for LEADER had both high 
and low CV risk categories. ‘High risk’ was defined as age > 50 years and a history of a 
previous CV event while ‘low risk’ patients were older (> 60 years) with a risk factor for CV 
disease, such as microalbuminuria. The study investigators anticipated that a majority of trial 
subjects would be in the ‘low risk’ category but it emerged that 81.3% were high risk at 
baseline. This is a very similar proportion to that seen in SUSTAIN 6 (83%) while all patients 
in the EMPA-REG OUTCOME study had established CV disease. In the subgroup analysis 
of LEADER, the benefit from liraglutide was only seen in the ‘high risk’ cohort (and there 
was a similar heterogeneity for low eGFR (which in patients with T2DM is essentially a 
marker of high CV risk). So, currently the CVOT findings cannot be extrapolated to the 
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whole T2DM population, although some national guidelines (e.g. Canada [54]) have already 
recommended that established CV disease should lead to earlier consideration of those agents 
shown to provide CV risk reduction. 
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Drug summary box 
Drug name Liraglutide 
Phase IV 
Indication Treatment of adults with type 2 diabetes mellitus to achieve 
glycemic control 
Mechanism of action Glucagon-like peptide-1 receptor agonist 
Route of administration Subcutaneous 
Chemical structure C172H265N43O51 
 
 
 
Pivotal trial(s) [12, 13, 14, 15, 16, 17, 18, 42] 
 
 
 
 
